Höllt V
Naunyn Schmiedebergs Arch Pharmacol. 1977;297 Suppl 1:S49-50. doi: 10.1007/BF00587775.
Using tritiated opiates with a high specific radioactivity, a high affinity binding to brain homogenates has been observed in vitro. Strong evidence was given that this type of binding is due to the interaction of labelled opiates with their specific receptors in the brain, since the ability of a wide variety of opiates to inhibit this binding corresponds very well with the potency of the drugs to produce their pharmacological effects in vivo. We have found that the simultaneous injection of labelled opiates into animals together with high doses of nonradioactive opiates decreases the brain concentration of the labelled drug. This displacement from brain satisfies criteria similar to those used for the identification of the opiate receptor in vitro. Furthermore, opiates produce their pharmacological effects in the same dose range in which they are able to displace a radiolabelled opiate from the brain. This strongly suggests that the receptor occupation by opiates can be identified by concentration changes in the brain of living animals.
使用具有高比放射性的氚标记阿片类药物,在体外观察到其与脑匀浆有高亲和力结合。有强有力的证据表明,这种结合类型是由于标记的阿片类药物与其在脑中的特异性受体相互作用所致,因为多种阿片类药物抑制这种结合的能力与这些药物在体内产生药理作用的效力非常吻合。我们发现,将标记的阿片类药物与高剂量的非放射性阿片类药物同时注射到动物体内,会降低标记药物在脑中的浓度。这种从脑中的置换符合类似于体外鉴定阿片受体所使用的标准。此外,阿片类药物在能够从脑中置换放射性标记阿片类药物的相同剂量范围内产生其药理作用。这有力地表明,阿片类药物对受体的占据可以通过活体动物脑中的浓度变化来确定。